The University of Oxford has started recruiting for a Phase 1/2 human challenge trial of a paratyphoid vaccine candidate, the university announced last week. The University of Maryland School of Medicine developed the oral candidate (CVD 1902) to protect against Salmonella Paratyphi infection, per the press release.
An Oxford researcher commented that a licensed paratyphoid vaccine is “desperately needed” due to “increasing antibiotic resistance.”